Astra ditches a Duo
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Roche trims its pipeline again
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
Lynparza/Imfinzi won’t progress in ovarian cancer, and another ceralasertib study fails.
Belvarafenib heads back to Hanmi and LY6G6D targeting takes a blow.
